The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...
Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today it has ex...
Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a st...
Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Kimiaki Tanaka), through its subsidiary Zeon Specialty Materials Inc. (Californi...
Partnership to leverage the Helix® Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Ad...
© 2025 Biopharma Boardroom. All Rights Reserved.
